October 23, 2020
Daiichi Sankyo said on October 22 that the first patient has been dose in a PI study for DS-1055, an immuno-oncology therapy targeting the GARP (glycoprotein-A repetitions predominant) protein, in certain patients with solid tumors in Japan and the US...read more